Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?

CONCLUSIONS: Germline BRCA 1/2 mutations are associated with a higher hematologic toxicity in patients with ovarian cancer who underwent platinum-based chemotherapy.
PMID: 31079832 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - May 8, 2019 Category: Cancer & Oncology Authors: Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P Tags: Gynecol Oncol Source Type: research